Microsphere antibody coupling compound, detection reagent, detection reagent card and detection kit for influenza A / B virus antigen detection
By developing microsphere antibody-conjugated complexes for influenza A/B viruses, the existing detection methods are solved, and high sensitivity and high accuracy detection is achieved, and raw materials are achieved. Low cost, no large equipment required, and short inspection time.
Patent Information
- Application Number
- CN202411438666.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2024-12-03
AI Technical Summary
The existing influenza A and B virus infection detection methods have problems such as high cost, slow speed, low sensitivity and accuracy.
Develop a microsphere antibody-conjugated complex for influenza A/B virus antigen detection by mixing microspheres, influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies and using blocking The liquid and storage solution were blocked and stored to prepare detection reagents with high sensitivity and specificity.
High sensitivity and high accuracy detection of influenza A and B virus infections has been achieved. The raw material cost is low, and the detection does not require large equipment, the time is short, and there are no false positive or false negative results.
Smart Images

Figure BDA0005085778090000101
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of antigen detection, and in particular relates to a microsphere-antibody coupling complex, a detection reagent, a detection reagent card and a detection kit for detecting influenza A / B virus antigens. Background Art
[0002] Influenza is a common infectious respiratory disease. Currently, influenza viruses are divided into four types: Influenza A Virus, Influenza B Virus, Influenza C Virus, and Influenza D Virus. Symptoms associated with influenza virus infection range from mild respiratory diseases limited to the upper respiratory tract characterized by fever, sore throat, runny nose, cough, headache, muscle pain, and fatigue, to severe pneumonia or even fatal pneumonia caused by influenza virus or secondary bacterial infection of the lower respiratory tract. In some cases, influenza virus infection can even induce some non-respiratory complications that affect the heart, central nervous system, or other organ systems.
[0003] Among them, influenza A and B viruses are the most widely spread among humans, so the diagnosis of influenza A and B virus infections is particularly important. There are four main diagnostic methods: (1) Virus culture method: Advantages: high specificity (>95%), ability to characterize novel viruses, ability to monitor antiviral sensitivity and antigenic drift; (2) Disadvantages: slow, requires specialized skills and equipment, and has lower sensitivity than RT-PCR; (3) RT-PCR method: Advantages: high specificity (>99%), high sensitivity (>99%), multiplexing, automation at relatively high throughput, moderate speed, and can be used to simultaneously type and subtype viruses; Disadvantages: expensive, more prone to false positive results (caused by nucleic acid contamination) than virus culture; (4) Rapid antigen test method: Advantages: rapid (15 minutes), instant detection, low cost, and can detect both influenza A and influenza B; Disadvantages: low sensitivity (50%–70%), prone to false negative results (96% negative predictive value), and cannot provide subtype information; (5) Rapid molecular assay method: Advantages: rapid (15 minutes), instant detection, high specificity (>99%), good sensitivity (66%–100%); Disadvantages: expensive.
[0004] From the above, we can see that the existing detection methods for influenza A and B virus infection have the problems of high cost, slow speed, low sensitivity and low accuracy. Summary of the invention
[0005] The present invention has developed a microsphere-antibody coupling complex for influenza A / B virus antigen detection, which can be used for the detection of influenza A / B virus antigens, thereby realizing the diagnosis of influenza A and B virus infection, and its detection sensitivity and accuracy are relatively high; the raw material cost is low, the preparation is simple; the detection does not require detection equipment, and the detection time is short.
[0006] In order to achieve the above object, the present invention can adopt the following technical solutions:
[0007] On one hand, the present invention provides a microsphere-antibody coupling complex for influenza A / B virus antigen detection, and the preparation method thereof comprises: mixing microspheres, influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies, coupling, and blocking to obtain the microsphere-antibody coupling complex.
[0008] Preferably, the coupling comprises: shaking the reaction at a temperature of 20°C-30°C for 30s-5h.
[0009] Preferably, the blocking method comprises: shaking the coupled conjugate and the blocking solution at a temperature of 20°C-30°C.
[0010] Preferably, the above-mentioned blocking solution includes a first blocking agent and a first surfactant; the blocking solution satisfies one or more combinations of the following conditions: (a) the first blocking agent is selected from BSA and / or casein; and / or the mass fraction of the first blocking agent is 0.1%-20%; (b) the first surfactant is selected from one or more combinations of Tween, coconut fatty acid diethanolamide, fatty acid glyceride or polyoxyethylene fatty alcohol ether; and / or the volume fraction of the first surfactant is 0.01%-10%.
[0011] Preferably, the reaction product after the blocking is washed with a washing solution and / or preserved with a preservation solution; wherein,
[0012] The cleaning solution satisfies one or more combinations of the following conditions: (a) the cleaning solution is selected from one or more combinations of HEPES solution, MES solution, boric acid buffer, PBS buffer or Tris-HCL solution; (b) the concentration of the cleaning solution is 10 mM-1000 mM; (c) the pH is 2-10;
[0013] The preservation solution includes a second blocking agent, a protein protective agent, a second surfactant and a first preservative, and the preservation solution satisfies one or more combinations of the following conditions: (a) the second blocking agent is selected from BSA and / or casein; and / or the mass fraction of the second blocking agent is 0.1-50%; (b) the protein protective agent is selected from one or more combinations of glucose, sucrose, trehalose or fructose; and / or the mass fraction of the protein protective agent is 0.1%-50%; (c) the second surfactant is selected from one or more combinations of Tween, coconut fatty acid diethanolamide, fatty acid glyceride or polyoxyethylene fatty alcohol ether; and / or the volume fraction of the second surfactant is 0.01%-10%; (d) the volume fraction of the first preservative is 0.01%-10%.
[0014] Preferably, the microspheres are activated before being coupled with influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies; the activation comprises: after the microspheres are mixed with an activation buffer, an activator is added for activation, and the activation satisfies one or more combinations of the following conditions: (a) the activation buffer is selected from one or more combinations of HEPES solution, MES solution, boric acid buffer, PBS buffer or Tris-HCL solution; and / or the concentration of the activation buffer is 1 mM-1000 mM; (b) the activator is EDC and / or NHS; and / or the concentration of the activator is 0.1 mg / mL-500 mg / mL.
[0015] Another aspect of the present invention provides a detection reagent for detecting influenza A / B virus antigens, comprising the microsphere-antibody coupling complex for detecting influenza A / B virus antigens of the present invention.
[0016] Another aspect of the present invention provides a detection reagent card for influenza A / B virus antigen detection, comprising a marking pad, wherein the marking pad is marked with the microsphere-antibody coupling complex for influenza A / B virus antigen detection of the present invention.
[0017] In another aspect, the present invention provides a detection kit for influenza A / B virus antigen detection, which comprises the detection reagent card of the present invention and a sample processing solution.
[0018] Preferably, the sample processing liquid comprises: a buffer, a third surfactant and a second preservative Proclin-300; the sample processing liquid satisfies one or more combinations of the following conditions: (a) the buffer is selected from one or more combinations of Tris-Hcl solution, PBS buffer, boric acid buffer, phosphate buffer or MES solution; and or the concentration of the buffer is 0.01M-10M; (b) the third surfactant is selected from TritionX-100 and / or Tween; and / or the volume fraction of the third surfactant is 0.01%-1%; (c) the second preservative is selected from Proclin-300, and / or the volume fraction of the second preservative is 0.01%-1%.
[0019] The beneficial effects of the present invention include at least:
[0020] (1) The influenza A / B virus antigen detection kit (latex method) prepared based on the microsphere-antibody coupling complex provided by the present invention detects influenza A / B virus antigens with high sensitivity, strong specificity and excellent accuracy.
[0021] (2) The influenza A / B virus antigen detection kit (latex method) prepared by the microsphere-antibody coupling complex provided by the present invention has low raw material cost, simple preparation method, does not require large-scale detection equipment during detection, is convenient and fast; and has a short detection time (detection can be completed in 10min-20min). DETAILED DESCRIPTION
[0022] The examples are provided to better illustrate the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention.
[0023] The terms used herein are only used to describe specific embodiments and are not intended to limit the present disclosure. Unless the context has a significantly different meaning, expressions in the singular include expressions in the plural. As used herein, it should be understood that terms such as "include", "have", "include" are intended to indicate the presence of features, numbers, operations, components, parts, elements, materials or combinations. The terms of the present invention are disclosed in the specification, and are not intended to exclude the possibility that one or more other features, numbers, operations, components, parts, elements, materials or combinations thereof may exist or may be added. As used herein, " / " may be interpreted as "and" or "or", depending on the circumstances.
[0024] In the present invention, the term "M" represents "mol / L" such as "mM" means "mmol / L", and so on.
[0025] In the present invention, the blocking solution, the preservation solution, the cleaning solution and the sample processing solution are all solutions with water as the medium.
[0026] In the present invention, the term "mass fraction" (M / V) refers to the mass percentage of the target substance in the aqueous medium. For example, in the sealing liquid, "the mass fraction of the first sealing agent is 0.1%-20%" refers to the mass percentage of the first sealing agent in the aqueous medium of the sealing liquid; the others are equivalent; the term "volume fraction" (V / V) refers to the mass percentage of the target substance in the aqueous medium. For example, in the sealing liquid, "the volume fraction of the first surfactant is 0.01%-10%" refers to the volume percentage of the first sealing agent in the aqueous medium of the sealing liquid; the others are equivalent.
[0027] The embodiment of the present invention provides a microsphere-antibody coupling complex for influenza A / B virus antigen detection. The preparation method thereof comprises mixing microspheres, influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies, coupling, and blocking to obtain the microsphere-antibody coupling complex.
[0028] It should be noted that the present invention has found that when the microspheres, influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies are coupled, the coupling efficiency of the microspheres, influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies for competitive binding is better than the efficiency of coupling by adding influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies in sequence; for example, the microspheres are first reacted with influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies respectively, and then mixed. Although the prepared kit has a strong detection sensitivity for influenza A and influenza B, there is a false positive for influenza A; for another example, the microspheres are first coupled with influenza B virus monoclonal antibodies, and then influenza A virus monoclonal antibodies are added for coupling. The prepared kit has a low sensitivity for influenza A and influenza B. The detection sensitivity of influenza A is low, and there are missed detections; although the detection sensitivity of influenza B is very strong, there are false positives; for another example, the microspheres are first coupled with influenza A virus monoclonal antibodies, and then influenza B virus monoclonal antibodies are added for coupling to prepare a kit; the microspheres are first coupled with influenza B virus monoclonal antibodies, and then influenza A virus monoclonal antibodies are added for coupling to prepare a kit; the kit prepared by the coupling method of the present invention has stronger detection sensitivity for influenza A and influenza B than other coupling methods, and there is no false positive; in addition, the coupling time in the present invention is shortened by about half compared with other methods; in addition, the operation of detecting influenza A / B virus antigens based on the microsphere-antibody coupling complex of the present invention is fast, simple, and economical.
[0029] It should also be noted that the microspheres in the present invention are all microspheres known in the art, preferably colored microspheres, which can be divided into carboxyl colored microspheres and streptavidin colored microspheres according to surface functional groups; they all have different particle sizes, and conventional particle sizes are 200nm, 300nm, and 400nm. Under the same mass, the larger the particle size, the higher the sensitivity, but the greater the occurrence of non-specific reactions; the mass ratio of microspheres to antibodies will also affect the sensitivity. When the microspheres are of the same mass, theoretically, the more antibodies are added, the higher the sensitivity, but when the binding of antibodies to microspheres reaches saturation, the sensitivity will not change even if too much antibody is added.
[0030] In some specific examples, the coupling comprises: shaking the reaction at a temperature of 20° C.-30° C. for 30 s-5 h.
[0031] It should be noted that the reaction of the above-mentioned microspheres and influenza A virus monoclonal antibodies is preferably oscillated at 20°C-30°C for 30s-5h, such as 28°C for 1h, 25°C for 3h, or 22°C for 4h; the oscillation reaction is a well-known operation in the art, and has no specific meaning, and it can be oscillated using equipment known in the art; similarly, the conditions for the reaction of the microspheres and influenza A virus monoclonal antibodies with influenza B virus monoclonal antibodies after the reaction can also be preferably oscillated at 20°C-30°C for 0.5h-5h, such as 28°C for 1h, 25°C for 3h, or 22°C for 4h. In addition, in order to fully couple the antibody to the microspheres, the oscillation parameters can be selected from 10rpm / min-80rpm / min, such as 20rpm / min, 40rpm / min, or 60rpm / min.
[0032] In some specific examples, the blocking method includes: shaking the coupled conjugate and the blocking solution at a temperature of 20°C-30°C.
[0033] It should be noted that the microspheres need to be blocked after being coupled with the influenza A virus monoclonal antibody and the influenza B virus monoclonal antibody. The blocking process is also to oscillate the second reactant obtained after coupling the microspheres with the influenza A virus monoclonal antibody and the influenza B virus monoclonal antibody with the blocking solution at a temperature of 20°C-30°C, such as oscillating at 23°C, 25°C, or 27°C.
[0034] In some specific examples, the above-mentioned blocking solution includes a first blocking agent and a first surfactant; the blocking solution satisfies one or more combinations of the following conditions:
[0035] (a) the first blocking agent is selected from BSA and / or casein; and / or the mass fraction of the first blocking agent is 0.1%-20%; specifically, the blocking solution contains a blocking agent, and the blocking agent can be selected from one or both of BSA and casein, with a mass fraction of 0.1%-20%, such as 1%-15%, 5%-12%, 8%-10%, etc., or 7%, 9%, 13% or 15%, etc.;
[0036] (b) the first surfactant is selected from one or more combinations of Tween, coconut fatty acid diethanolamide, fatty acid glyceride or polyoxyethylene fatty alcohol ether; and / or the mass fraction of the first surfactant is 0.01%-10%; specifically, the blocking solution also includes a surfactant, and the surfactant (i.e., the first surfactant) here is preferably Tween; the volume fraction can be 0.01%-10%, such as 0.05%-8%, 0.1%-7%, 1%-5%, 2%-9%, etc.; or 4%, 6% or %7%, etc.
[0037] It should also be noted that the above-mentioned sealing liquid may satisfy one of the above-mentioned conditions, or may satisfy both of the above-mentioned conditions at the same time, preferably satisfying both of the above-mentioned conditions at the same time.
[0038] In some specific examples, the reaction product after the blocking is washed with a washing solution and / or preserved with a preservation solution;
[0039] The cleaning fluid satisfies one or more of the following conditions:
[0040] (a) the cleaning solution is selected from one or more combinations of HEPES solution, MES solution, boric acid buffer, PBS buffer or Tris-HCl solution; specifically, after the blocking reaction, a specific cleaning is required to remove excess antibodies or other substances other than the microsphere-antibody coupling complex, and the cleaning solution is preferably one or more combinations of HEPES solution, MES solution, boric acid buffer, PBS buffer or Tris-HCl solution;
[0041] (b) the concentration of the cleaning solution is 10mM-1000mM, such as 50mM-950mM, 100mM-800mM, 200mM-500mM or 300mM-400m, etc.;
[0042] (c) pH 2-10, such as 3, 5, 7 or 9;
[0043] The preservation solution includes a second blocking agent, a protein protective agent, a second surfactant and a first preservative, and the preservation solution meets one or more of the following conditions:
[0044] (a) the second blocking agent is selected from BSA and / or casein; and / or the mass fraction of the second blocking agent is 0.1%-50%; such as 1%-45%, 5%-40%, 10%-15% or 12%-30%, etc.; or 7%, 14%, 22%, 27%, 36% or 42%, etc.;
[0045] (b) the protein protective agent is selected from one or more combinations of glucose, sucrose, trehalose or fructose; and / or the mass fraction of the protein protective agent is 0.1%-50%; such as 1%-45%, 5%-40%, 10%-15% or 12%-30%, etc.; or 12%, 18%, 23%, 27% or 29%, etc.;
[0046] (c) the second surfactant is selected from one or more combinations of Tween, coconut fatty acid diethanolamide, fatty acid glyceride or polyoxyethylene fatty alcohol ether; and / or the volume fraction of the second surfactant is 0.01%-10%; such as 1%-45%, 5%-40%, 10%-15% or 12%-30%, etc.; or 7%, 14%, 22%, 27%, 36% or 42%, etc.;
[0047] (d) the first preservative is selected from sodium azide; and / or the volume fraction of the first preservative is 0.01%-10%; such as 1%-45%, 5%-40%, 10%-15% or 12%-30%, etc.; or 7%, 14%, 22%, 27%, 36% or 42%, etc.
[0048] It should be noted that the above-mentioned cleaning solution may satisfy one of the above-mentioned conditions, or may satisfy multiple of the above-mentioned conditions, and preferably may satisfy all of the above-mentioned conditions (three kinds) at the same time; similarly, the above-mentioned preservation solution may satisfy one of the above-mentioned conditions, or may satisfy multiple of the above-mentioned conditions, and preferably may satisfy all of the above-mentioned conditions (four kinds) at the same time; it should also be noted that after the second reactant is blocked, the cleaning solution is used for cleaning, and the preservation solution is used for preservation, then the cleaning and preservation may satisfy one or more of the conditions of the above-mentioned cleaning solution and the preservation solution, and preferably may satisfy all of the conditions of the above-mentioned cleaning solution and the preservation solution at the same time.
[0049] In some specific examples, the microspheres are activated before being coupled with influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies; the activation includes: after the microspheres are mixed with an activation buffer, an activator is added for activation, and the activation satisfies one or more combinations of the following conditions:
[0050] (a) the activation buffer is selected from one or more combinations of HEPES solution, MES solution, borate buffer, PBS buffer or Tris-HCl solution; and / or the concentration of the activation buffer is 1 mM-1000 mM; such as 5 mM-950 mM, 10 mM-900 mM, 100 mM-800 mM, 300 mM-500 mM, 400 mM-700 mM, etc.; or 150 mM, 250 mM, 350 mM, 550 mM or 800 mM, etc.;
[0051] (b) The activator is selected from EDC and / or NHS; and / or the concentration of the activator is 0.1 mg / mL-500 mg / mL; such as 1 mg / mL, -450 mg / mL, 50 mg / mL-480 mg / mL, 150 mg / mL-400 mg / mL, 300 mg / mL-450 mg / mL, etc.; or 100 mg / mL, 200 mg / mL, 300 mg / mL or 420 mg / mL, etc.
[0052] It should be noted that it should be understood that in order to increase the coupling efficiency of the microsphere-antibody coupling complex, the microspheres can be activated before coupling in the present invention; the activation method is well known in the art, and preferably the above-mentioned activation method is used for activation, which can significantly increase the coupling efficiency.
[0053] It should also be noted that the above activation may satisfy one of the above-mentioned conditions, or may satisfy two of the above-mentioned conditions, and preferably satisfies all (two) of the above-mentioned conditions at the same time.
[0054] The embodiment of the present invention further provides a detection reagent for influenza A / B virus antigen detection, including the microsphere-antibody coupling complex for influenza A / B virus antigen detection of the present invention.
[0055] It should be noted that the microsphere-antibody coupling complex of the present invention can be prepared into a detection reagent by mixing with other detection reagent excipients; wherein the other detection reagent excipients are reagents known in the art, such as buffer solutions, preservatives, etc.
[0056] The embodiment of the present invention further provides a detection reagent card for influenza A / B virus antigen detection, comprising a marking pad, wherein the marking pad is marked with the microsphere-antibody coupling complex for influenza A / B virus antigen detection of the present invention.
[0057] It should be noted that the microsphere-antibody coupling complex marker for influenza A / B virus antigen detection in the present invention can be sprayed on a blank release pad and dried to form a marking pad; then the bottom plate, and the sample pad, marking pad, nitrocellulose membrane and absorbent paper arranged in sequence from the sample application end on the surface of the bottom plate are constructed into a detection reagent card for influenza A / B virus antigen detection; in addition, the bottom plate is a bottom plate known in the art, and a PVC bottom plate is generally selected.
[0058] The embodiment of the present invention further provides a detection kit for influenza A / B virus antigen detection, which includes the detection reagent card of the present invention and a sample processing solution.
[0059] It should be noted that, on the basis of the above-mentioned test reagent card for influenza A / B virus antigen detection, a sample processing solution, sheep anti-mouse IgG and a plastic card shell can be added to prepare a test kit for influenza A / B virus antigen detection, which is more convenient to carry; in addition, the test kit can also be packaged in an aluminum foil bag.
[0060] In some specific examples, the sample processing liquid includes: a buffer, a third surfactant and a second preservative; the sample processing liquid satisfies one or more combinations of the following conditions:
[0061] (a) the buffer is selected from one or more combinations of Tris-HCl solution, PBS buffer, borate buffer, phosphate buffer or MES solution; and or the concentration of the buffer is 0.01M-10M, such as 0.1M-9.5M, 2M-9M, 5M-8M, 7M-8.5M; or 3M, 6M or 9M, etc.;
[0062] (b) the third surfactant is selected from TritionX-100 and / or Tween; and / or the volume fraction of the third surfactant is 0.01%-1%, such as 0.1%-0.9%, 0.4%-0.7% or 0.6%-0.8%, etc.; or 0.05%, 0.2%, 0.5% or 0.7%, etc.;
[0063] (c) the second preservative is selected from Proclin-300; and / or the volume fraction of the second preservative is 0.01%-1%, such as 0.1%-0.9%, 0.4%-0.7% or 0.6%-0.8%, etc.; or 0.05%, 0.2%, 0.5% or 0.7%, etc.
[0064] It should be noted that the sample processing solution may satisfy one of the above three conditions, or may satisfy multiple conditions at the same time, and preferably satisfies all three conditions at the same time.
[0065] In order to better understand the present invention, the content of the present invention is further explained below in conjunction with specific examples, but the content of the present invention is not limited to the following examples.
[0066] In the following example, the preparation of the influenza A / B virus antigen detection kit (latex method) is carried out according to the following steps:
[0067] (1) Preparation of labeling pad: The microsphere-antibody coupling complex mixture was diluted 10 times with a microsphere diluent (the microsphere diluent was added with a 20 mM HEPES aqueous solution (pH = 6), which contained 5% (M / V) tris (hydroxymethyl) aminomethane, 2% (M / V) bovine serum albumin, 5% (M / V) glucose, 0.1% (V / V) Proclin-300, and 0.5% (V / V) Tween); the diluted microsphere-antibody coupling complex mixture was sprayed on a blank release pad using an XYZ three-dimensional film spraying instrument, and dried at 37°C ± 2°C for 1 h to prepare a labeling pad;
[0068] (2) Using an XYZ three-dimensional film spray gold scribing instrument, monoclonal antibodies against influenza A virus and monoclonal antibodies against influenza B virus are streaked on a nitrocellulose membrane, and dried at 37°C ± 2°C or 57°C ± 2°C for 1-5 days to form two test lines; sheep anti-mouse IgG is streaked on a nitrocellulose membrane, and dried to form a quality control line, which is located at one end close to the absorbent paper, and the other two test lines are located downwards;
[0069] (3) Starting from the sample application end, the sample pad, the marking pad, the nitrocellulose membrane and the absorbent paper are sequentially assembled on the PVC bottom plate, cut into strips by a chopper, and the reagent strip is assembled on a plastic card shell, and finally packaged into an aluminum foil bag together with a desiccant to prepare an influenza A / B virus antigen detection kit (latex method).
[0070] 1. Kit Preparation
[0071] Example 1
[0072] (1) Activation buffer: Add 1 mL of 20 mM HEPES solution (pH = 6) to 1 mg of red carboxyl microspheres (particle size 300 mm) to obtain a mixed solution 1;
[0073] (2) Activation: Add 10 uL of 10 mg / mL EDC (1-ethyl-(3-dimethylaminopropyl) carbodiimide) and 10 uL of 10 mg / mL NHS solution to the mixed solution 1 for mixing and activation to obtain a mixed solution 2;
[0074] (3) Coupling: first add 50 μg of influenza A virus monoclonal antibody, then add 50 μg of influenza B virus monoclonal antibody, and react at 25° C. (60 rpm / min) for 3 hours to obtain a mixed solution 3;
[0075] (4) Blocking: Add 100 μL of water-based blocking solution (5% (M / V) BSA, 0.5% (V / V) Tween) to mixed solution 3, and shake at room temperature for 3 hours to obtain mixed solution 4;
[0076] (5) Cleaning: Use 1 mL of cleaning solution (20 mM boric acid aqueous solution, pH = 8) to clean the mixed solution 4, centrifuge at 1000 rpm for 15 min, and remove the supernatant to obtain the microsphere-antibody coupling complex;
[0077] (6) Storage: The microsphere-antibody coupling complex is stored in 1 mL of a storage solution (20 mM HEPES aqueous solution (pH = 6), containing 5% (M / V) BSA, 5% (M / V) glucose, 0.5% (V / V) Tween, and 0.1% (V / V) sodium azide) to obtain a microsphere-antibody coupling complex mixed solution;
[0078] (7) The microsphere-antibody coupling complex mixture is prepared according to the preparation steps of the above-mentioned influenza A / B virus antigen detection kit (latex method) to obtain an influenza A / B virus antigen detection kit (latex method).
[0079] Comparative Example 1
[0080] The difference between Example 2 and Example 1 is that the coupling step is different. The coupling step of Example 2 is: the mixed solution 2 is divided into two tubes, 50ug of influenza A virus monoclonal antibody and 50ug of influenza B virus monoclonal antibody are added respectively, and then the mixture is shaken (60rpm / min) at 25°C for 3 hours and then mixed into one tube to obtain a mixed solution 3; the other steps are the same as Example 1, and an influenza A / B virus antigen detection kit (latex method) is prepared.
[0081] Comparative Example 2
[0082] The difference between Example 3 and Example 1 is that the coupling steps are different. The coupling steps of Example 3 are: first, 50ug of influenza B virus monoclonal antibody is added, and the reaction is oscillated at 25°C for 3 hours; then, 50ug of influenza A virus monoclonal antibody is added, and the reaction is oscillated at 25°C for 3 hours; the other steps are the same as Example 1, and an influenza A / B virus antigen detection kit (latex method) is prepared.
[0083] Comparative Example 3
[0084] The difference between Example 4 and Example 1 is that the coupling step is different. The coupling step of Example 4 is: first add 50ug of influenza A virus monoclonal antibody, shake and react at 25°C for 3 hours, then add 50ug of influenza B virus monoclonal antibody, shake and react at 25°C for 3 hours; the other steps are the same as Example 1, and an influenza A / B virus antigen detection kit (latex method) is prepared.
[0085] 2. Test kit test
[0086] Take 30 nasopharyngeal swab samples (10 influenza A-positive and influenza B-negative samples, 10 influenza B-positive and influenza A-negative samples, and 10 samples that are negative for both influenza A and B), mix them with a sample treatment solution (an aqueous solution including 25 mM Tris-Hc (PH=7.2), 0.5% (V / V) TritionX-100, 1% (M / V) casein, and 0.1% (V / V) Proclin-300) to obtain samples to be tested.
[0087] The above 30 samples to be tested were tested using the influenza A / B virus antigen detection kit (latex method) prepared in Example 1 and the influenza A / B virus antigen detection kit (latex method) prepared in Comparative Examples 1 to 3, and the results are shown in Table 1 below.
[0088] Table 1 Test samples of examples and comparative examples
[0089]
[0090] Note: Positive +, the more + signs, the stronger the positive; Negative -
[0091] From Table 1 above, we can know that:
[0092] The influenza A / B virus antigen detection kit (latex method) prepared in Example 1 has a stronger detection sensitivity for influenza A and influenza B than both comparative examples 1 and 2, and there is no false positive;
[0093] The influenza A / B virus antigen detection kit (latex method) prepared in Comparative Example 1 has a strong detection sensitivity for influenza A and influenza B, but there are false positives for influenza A;
[0094] The influenza A / B virus antigen detection kit (latex method) prepared in Comparative Example 2 has a low sensitivity for influenza A detection and may miss detections; although the sensitivity for influenza B detection is very strong, there may be false positives;
[0095] The influenza A / B virus antigen detection kit (latex method) prepared in Comparative Example 3 had no false positives for influenza A and influenza B; however, it had low sensitivity for influenza A and influenza B and there were cases of missed detection.
[0096] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.
Claims
1. A microsphere-antibody coupling complex for influenza A / B virus antigen detection, characterized in that: The preparation method comprises: mixing microspheres, influenza A virus monoclonal antibodies and influenza B virus monoclonal antibodies, coupling and blocking to obtain a microsphere-antibody coupling complex.
2. The microsphere-antibody coupling complex for influenza A / B virus antigen detection according to claim 1, characterized in that: Conjugation includes: Oscillate the reaction at 20°C-30°C for 30s-5h.
3. The microsphere-antibody coupling complex for influenza A / B virus antigen detection according to claim 1 or 2, characterized in that: The blocking method includes: shaking the coupled conjugate and the blocking solution at a temperature of 20°C-30°C.
4. The microsphere-antibody coupling complex for influenza A / B virus antigen detection according to claim 3, characterized in that: The blocking solution includes a first blocking agent and a first surfactant; the blocking solution satisfies one or more combinations of the following conditions: (a) the first blocking agent is selected from BSA and / or casein; and / or the mass fraction of the first blocking agent is 0.1%-20%; (b) the first surfactant is selected from one or more combinations of Tween, coconut fatty acid diethanolamide, fatty acid glyceride or polyoxyethylene fatty alcohol ether; and / or the volume fraction of the first surfactant is 0.01%-10%.
5. The microsphere-antibody coupling complex for influenza A / B virus antigen detection according to claim 1, 2 or 4, characterized in that: The blocked reactants are washed with a washing solution and / or stored with a storage solution; The cleaning fluid satisfies one or more of the following conditions: (a) the cleaning solution is selected from one or more combinations of HEPES solution, MES solution, borate buffer, PBS buffer or Tris-HCl solution; (b) the concentration of the cleaning solution is 10 mM-1000 mM; (c) pH 2-10; The preservation solution includes a second blocking agent, a protein protective agent, a second surfactant and a first preservative, and the preservation solution satisfies one or more combinations of the following conditions: (a) the second blocking agent is selected from BSA and / or casein; and / or the mass fraction of the second blocking agent is 0.1%-50%; (b) the protein protective agent is selected from one or more combinations of glucose, sucrose, trehalose or fructose; and / or the mass fraction of the protein protective agent is 0.1%-50%; (c) the second surfactant is selected from one or more combinations of Tween, coconut fatty acid diethanolamide, fatty acid glyceride or polyoxyethylene fatty alcohol ether; and / or the volume fraction of the second surfactant is 0.01%-10%; (d) the first preservative is selected from sodium azide; and / or the volume fraction of the first preservative is 0.01%-10%.
6. The microsphere-antibody coupling complex for influenza A / B virus antigen detection according to claim 1, 2 or 4, characterized in that: Before coupling the microspheres with the influenza A virus monoclonal antibody and the influenza B virus monoclonal antibody, the microspheres are first activated; the activation includes: after the microspheres are mixed with the activation buffer, an activator is added for activation, and the activation satisfies one or more combinations of the following conditions: (a) the activation buffer is selected from one or more combinations of HEPES solution, MES solution, borate buffer, PBS buffer or Tris-HCl solution; and / or the concentration of the activation buffer is 1 mM-1000 mM; (b) The activator is selected from EDC and / or NHS; and / or the concentration of the activator is 0.1 mg / mL-500 mg / mL.
7. A detection reagent for influenza A / B virus antigen detection, characterized in that: The invention comprises a microsphere-antibody coupling complex for detecting influenza A / B virus antigens as described in any one of claims 1 to 6.
8. A test reagent card for influenza A / B virus antigen detection, characterized in that: The invention comprises a marking pad, wherein the marking pad is prepared by marking the microsphere-antibody coupling complex for influenza A / B virus antigen detection as claimed in any one of claims 1 to 6.
9. A test kit for detecting influenza A / B virus antigens, characterized in that: It comprises the detection reagent card and sample processing liquid as described in claim 8.
10. The detection kit for influenza A / B virus antigen detection according to claim 9, characterized in that: The sample processing liquid includes: a buffer, a third surfactant and a second preservative; the sample processing liquid satisfies one or more combinations of the following conditions: (a) the buffer is selected from one or more combinations of Tris-HCl solution, PBS buffer, borate buffer, phosphate buffer or MES solution; and or the concentration of the buffer is 0.01M-10M; (b) the third surfactant is selected from TritionX-100 and / or Tween; and / or the volume fraction of the third surfactant is 0.01%-1%; (c) the second preservative is selected from Proclin-300; and / or the volume fraction of the second preservative is 0.01%-1%.
